Research Article

**Author for correspondence:

E-mail Address: liviacarmo.bio@gmail.com

https://orcid.org/0000-0002-2131-7395

Institute of Biological Sciences, Federal University of Goiás, Goiânia, Goiás, 74690-900, Brazil

Search for more papers by this author

Raimundo F dos Santos Filho

https://orcid.org/0000-0002-7328-3801

Chemistry institute, Federal University of Bahia, Salvador, Bahia, 40170-115, Brazil

Search for more papers by this author

Amanda A de Oliveira

https://orcid.org/0000-0001-9389-4805

Institute of Tropical Pathology & Public Health, Federal University of Goiás, Goiânia, Goiás, 74690-900, Brazil

Search for more papers by this author

Felipe T Martins

Chemistry institute, Federal University of Goiás, Goiânia, Goiás, 74690-900, Brazil

Search for more papers by this author

Silvio Cunha

https://orcid.org/0000-0002-8822-517X

Chemistry institute, Federal University of Bahia, Salvador, Bahia, 40170-115, Brazil

Search for more papers by this author

Célia M de Almeida Soares

https://orcid.org/0000-0001-5378-9840

Institute of Biological Sciences, Federal University of Goiás, Goiânia, Goiás, 74690-900, Brazil

Search for more papers by this author

Maristela Pereira

*Author for correspondence: Tel.: +55 623 521 1110;

E-mail Address: maristelaufg@gmail.com

https://orcid.org/0000-0002-5482-8036

Institute of Biological Sciences, Federal University of Goiás, Goiânia, Goiás, 74690-900, Brazil

Search for more papers by this author

Published Online:20 Jan 2023https://doi.org/10.2217/fmb-2022-0133

View article

Abstract

Aims: Considering the need to identify new compounds with antifungal action, the activity of five 3-phenacylideneoxindoles compounds was evaluated. Materials & methods: The compounds were synthesized, and their antifungal activity was elucidated through minimum inhibitory concentration tests and interaction assay with other antifungals. Potential targets of compounds were predicted in silico. Results: 3-phenacylideneoxindoles compounds inhibited fungal growth with minimum inhibitory concentration and minimum fungicidal concentration ranging from 3.05 to 12.26 μM. The compounds demonstrated high selectivity index and presented a synergistic effect with itraconazole. In silico prediction revealed the pentafunctional AROM polypeptide, enolase, superoxide dismutase, catalase and kinases as proteins targets of the compound 4a. Conclusion: The results demonstrate that 3-phenacylideneoxindoles is a potential new class of antifungal compounds for paracoccidioidomycosis treatment.

Plain language summary

Patients affected by paracoccidioidomycosis (PCM) require long-term treatment, which commonly influences their adherence. In addition, only three drugs are in clinical use, which indicates the relevance of research in identifying new drugs for treating PCM. Thus, five drugs were tested in the laboratory to verify whether they could prevent the growth of the fungus without being toxic to humans. In addition, whether these compounds in combination with drugs used to treat PCM could be even more potent was evaluated. All compounds tested efficiently inhibited the growth of Paracoccidioides, the fungus that causes PCM. One drug was identified that, combined with itraconazole, decreased the required dose of both the discovered compound and itraconazole needed to inhibit fungal growth. Using computational tools, this work suggests how the new drug could act against the fungus. The results demonstrate a potential new treatment option, but more studies are needed to confirm the safety of these drugs.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Martinez R. New trends in paracoccidioidomycosis epidemiology. J. Fungi 3(1), 1 (2017).
Google Scholar
2. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLOS Negl. Trop. Dis. 2(9), e300 (2008).
MedlineGoogle Scholar
3. Shikanai-Yasuda MA, Mendes RP, Colombo AL et al. Brazilian guidelines for the clinical management of paracoccidioidomycosis. Rev. Soc. Bras. Med. Trop. 50(5), 715–740 (2017). •• Presents the consensus on paracoccidioidomycosis (PCM) that establish the guidelines of the clinical, diagnostic and treatment approach.
MedlineGoogle Scholar
4. Bocca AL, Amaral AC, Teixeira MM, Sato PK et al. Paracoccidioidomycosis: eco-epidemiology, taxonomy and clinical and therapeutic issues. Future Microbiol. 8(9), 1177–1191 (2013).
Google Scholar
5. Martinez R. Epidemiology of paracoccidioidomycosis. Rev. Inst. Med. Trop. São Paulo 57(Suppl. 19), 11–20 (2015).
Medline CASGoogle Scholar
6. Shikanai-Yasuda MA. Paracoccicidoidomycosis treatment. Rev. Inst. Med. Trop. São Paulo 57(Suppl. 19), 31–37 (2015).
Medline CASGoogle Scholar
7. do Carmo Silva L, de Oliveira AA, de Souza DR et al. Overview of antifungal drugs against paracoccidioidomycosis: how do we start, where are we, and where are we going? J. Fungi 6(4), 300 (2020). • Presents the history of development of the current antifungals used in the treatment of PCM as it presents the compounds already tested against the fungus.
Google Scholar
8. da Silva LS, Barbosa UR, Silva L do C et al. Identification of a new antifungal compound against isocitrate lyase of Paracoccidioides brasiliensis. Future Microbiol. 14(18), 1589–1606 (2019).
CASGoogle Scholar
9. Silva LC, Neves BJ, Gomes MN et al. Computer-aided identification of novel anti-paracoccidioidomycosis compounds. Future Microbiol. 13(13), 1523–1535 (2018).
CASGoogle Scholar
10. Wang J, Yun D, Yao J et al. Design, synthesis and QSAR study of novel isatin analogues inspired Michael acceptor as potential anticancer compounds. Eur. J. Med. Chem. 144, 493–503 (2018).
Medline CASGoogle Scholar
11. Klöck C, Jin X, Choi K et al. Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2. Bioorg. Med. Chem. Lett. 21(9), 2692–2696 (2011).
MedlineGoogle Scholar
12. Woodard CL, Li Z, Kathcart AK et al. Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases. J. Med. Chem. 46(18), 3877–3882 (2003).
Medline CASGoogle Scholar
13. Gupta A, Kalpana S, Malik J. Synthesis and In vitro antioxidant activity of new 3-substituted-2-oxindole derivatives. Indian J. Pharm. Sci. 74(5), 481 (2012).
Medline CASGoogle Scholar
14. Pajouhesh H, Parson R, Popp FD. Potential anticonvulsants VI: condensation of isatins with cyclohexanone and other cyclic ketones. J. Pharm. Sci. 72(3), 318–321 (1983).
Medline CASGoogle Scholar
15. Kaur J, Utreja D, Ekta et al. Recent developments in the synthesis and antimicrobial activity of indole and its derivatives. COS 16(1), 17–37 (2019). • Presents the advances in the synthesis of indole derivatives and antimicrobial properties exhibited by them.
CASGoogle Scholar
16. Özdemir A, Altintop MD, Kaplancıklı ZA et al. Synthesis and biological evaluation of pyrazoline derivatives bearing an indole moiety as new antimicrobial agents. Arch. Pharm. Pharm. Med. Chem. 346(6), 463–469 (2013).
Medline CASGoogle Scholar
17. Zhong F, Jiang C, Yao W et al. Molecular sieve mediated decarboxylative Mannich and aldol reactions of β-ketoacids. Tetrahedron Lett. 54(32), 4333–4336 (2013).
CASGoogle Scholar
18. Bai M, You Y, Chen Y-Z et al. An unprecedented protocol for the synthesis of 3-hydroxy-3-phenacyloxindole derivatives with indolin-2-ones and α-substituted ketones. Org. Biomol. Chem. 14(4), 1395–1401 (2016).
Medline CASGoogle Scholar
19. Thanikachalam PV, Maurya RK, Garg V, Monga V. An insight into the medicinal perspective of synthetic analogs of indole: a review. Eur. J. Med. Chem. 180, 562–612 (2019).
Medline CASGoogle Scholar
20. Bruker. Bruker. APEX2, SAINT e SADABS. Bruker AXS Inc., Madison., Bruker AXS Inc., Madison (2009).
Google Scholar
21. Sheldrick GM. A short history of SHELX. Acta Crystallog A. 64(1), 112–122 (2007).
MedlineGoogle Scholar
22. CLSI. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts, approved standard. Document M27 (2008). https://clsi.org/standards/products/microbiology/documents/m27/
Google Scholar
23. Rocha OB, do Carmo Silva L, de Carvalho Júnior MAB et al. In vitro and in silico analysis reveals antifungal activity and potential targets of curcumin on Paracoccidioides spp. Braz. J. Microbiol. 52(4), 1897–1911 (2021).
Medline CASGoogle Scholar
24. Jaccard P. Distribution de la flore alpine dans le Bassin des Dranses et dans quelques regiões voisines. Bulletin de la Société Vaudoise des Sciences Naturelles. La socit Vaudoise Des Sxi. Nat. 37, 241–272 (1901).
Google Scholar
25. Bajusz D, Rácz A, Héberger K. Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? J. Chem. 7(1), 1–13 (2015).
CASGoogle Scholar
26. Anderson S. Graphical representation of molecules and substructure-search queries in MACCStm. J. Mol. Graph. 2(3), 83–90 (1984).
CASGoogle Scholar
27. Berthold MR, Cebron N, Dill F et al. KNIME: the Konstanz Information Miner. In: Data Analysis, Machine Learning and Applications. Preisach CBurkhardt HSchmidt-Thieme LDecker R (Eds). Springer Berlin Heidelberg, Berlin, Heidelberg, 319–326 (2008).
Google Scholar
28. Beisken S, Meinl T, Wiswedel B et al. KNIME-CDK: Workflow-driven cheminformatics. BMC Bioinform. 14(1), 257 (2013).
MedlineGoogle Scholar
29. Keiser MJ, Roth BL, Armbruster BN et al. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 25(2), 197–206 (2007). •• Demonstrates the technique that quantitatively groups and relates proteins based on the chemical similarity of their ligands and proposes the PharmMapper server.
Medline CASGoogle Scholar
30. Waterhouse A, Bertoni M, Bienert S et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 46(W1), W296–W303 (2018).
Medline CASGoogle Scholar
31. Williams CJ, Headd JJ, Moriarty NW et al. MolProbity: more and better reference data for improved all-atom structure validation. Protein Sci. 27(1), 293–315 (2018).
Medline CASGoogle Scholar
32. Bhattacharya D, Nowotny J, Cao R, Cheng J. 3D refine: an interactive web server for efficient protein structure refinement. Nucleic acids Res. 44(W1), W406–W409 (2016).
Medline CASGoogle Scholar
33. Fourches D, Muratov E, Tropsha A. Trust, but verify II: A practical guide to chemogenomics data curation. J. Chem. Inf. Model. 56(7), 1243–1252 (2016).
Medline CASGoogle Scholar
34. OpenEye Scientific. OMEGA v.3.0.0.1: OpenEye Scientific Software, Santa Fe, NM. http://www.eyesopen.com
Google Scholar
35. Jakalian A, Jack DB, Bayly CI. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J. Comput. Chem. 23(16), 1623–1641 (2002).
Medline CASGoogle Scholar
36. OpenEye Scientific. QUACPAC v.1.7.0.2: OpenEye Scientific Software, Santa Fe, NM. http://www.eyesopen.com
Google Scholar
37. OpenEye Scientific. OEDocking v.3.2.0: OpenEye Scientific Software, Santa Fe, NM, USA. http://www.eyesopen.com
Google Scholar
38. McGann M. FRED and HYBRID docking performance on standardized datasets. J. Comput. Aided Mol. Des. 26(8), 897–906 (2012).
Medline CASGoogle Scholar
39. Edeson SJ, Jiang J, Swanson S et al. Studies on the stereochemical assignment of 3-acylidene 2-oxindoles. Org. Biomol. Chem. 12(20), 3201 (2014).
Medline CASGoogle Scholar
40. Jain AK, Sharma S, Vaidya A, Ravichandran V, Agrawal RK. 1,3,4-Thiadiazole and its derivatives: a review on recent progress in biological activities. Chem. Biol. Drug Des. 81(5), 557–576 (2013).
Medline CASGoogle Scholar
41. Khetmalis YM, Shivani M, Murugesan S, Chandra Sekhar KVG. Oxindole and its derivatives: a review on recent progress in biological activities. Biomed. Pharmacother. 141, 111842 (2021).
Medline CASGoogle Scholar
42. Restrepo A, Tabares C de BAM. In vitro susceptibility of Paracoccidioides brasiliensis yeast form to antifungal agents. Rev. Inst. Med. Trop. São Paulo 26(6), 322–328 (1984).
Medline CASGoogle Scholar
43. Bueno PSA, Rodrigues FAV, Santos JL et al. New inhibitors of homoserine dehydrogenase from Paracoccidioides brasiliensis presenting antifungal activity. J. Mol. Model. 25(11), 325 (2019).
Medline CASGoogle Scholar
44. Silva L do C, Tauhata SBF, Baeza LC et al. Argentilactone molecular targets in Paracoccidioides brasiliensis identified by chemoproteomics. Antimicrob. Agents Chemother. 62(11), e00737–18 (2018).
MedlineGoogle Scholar
45. do Carmo Silva L, Miranda MACM, de Freitas JV et al. Antifungal activity of Copaíba resin oil in solution and nanoemulsion against Paracoccidioides spp. Braz. J. Microbiol. 51(1), 125–134 (2020).
MedlineGoogle Scholar
46. Liu J, Jung JH, Liu Y. Antimicrobial compounds from marine invertebrates-derived microorganisms. Curr. Med. Chem. 23(25), 2892–2905 (2016).
Medline CASGoogle Scholar
47. Comess KM, McLoughlin SM, Oyer JA et al. Emerging approaches for the identification of protein targets of small molecules – a practitioners' perspective. J. Med. Chem. 61(19), 8504–8535 (2018).
Medline CASGoogle Scholar
48. Wang Y-H, Dong H-H, Zhao F et al. The synthesis and synergistic antifungal effects of chalcones against drug resistant Candida albicans. Bioorganic Med. Chem. Lett. 26(13), 3098–3102 (2016).
Medline CASGoogle Scholar
49. Bentley R, Haslam E. The Shikimate pathway – a metabolic tree with many branche. Crit. Rev. Biochem. Mol. Biol. 25(5), 307–384 (1990).
Medline CASGoogle Scholar
50. Nogueira SV, Fonseca FL, Rodrigues ML et al. Paracoccidioides brasiliensis enolase is a surface protein that binds plasminogen and mediates interaction of yeast forms with host cells. Infect. Immun. 78(9), 4040–4050 (2010).
Medline CASGoogle Scholar
51. Marcos CM, de Fátima da Silva J, de Oliveira HC, Moraes da Silva RA, Mendes-Giannini MJS, Fusco-Almeida AM. Surface-expressed enolase contributes to the adhesion of Paracoccidioides brasiliensis to host cells. FEMS Yeast Res. 12(5), 557–570 (2012).
Medline CASGoogle Scholar
52. Tamayo D, Muñoz JF, Lopez Á et al. Identification and analysis of the role of superoxide dismutases isoforms in the pathogenesis of Paracoccidioides spp. PLOS Negl. Trop. Dis. 10(3), e0004481 (2016).
MedlineGoogle Scholar
53. Tamayo D, Muñoz JF, Almeida AJ et al. Paracoccidioides spp. catalases and their role in antioxidant defense against host defense responses. Fungal Genet. Biol. 100, 22–32 (2017).
Medline CASGoogle Scholar
54. Caplan T, Lorente-Macías Á, Stogios PJ et al. Overcoming fungal echinocandin resistance through inhibition of the non-essential stress kinase Yck2. Cell Chem. Biol. 27(3), 269–282.e5 (2020).
Medline CASGoogle Scholar
55. Fuchs BB, Mylonakis E. Our paths might cross: the role of the fungal cell wall integrity pathway in stress response and cross talk with other stress response pathways. Eukaryot. Cell 8(11), 1616–1625 (2009).
Medline CASGoogle Scholar
56. Levin DE, Bartlett-Heubusch E. Mutants in the S. cerevisiae PKC1 gene display a cell cycle-specific osmotic stability defect. J. Cell Biol. 116(5), 1221–1229 (1992).
Medline CASGoogle Scholar
57. Jung K-W, Lee Y, Huh EY et al. Rad53- and Chk1-dependent DNA damage response pathways cooperatively promote fungal pathogenesis and modulate antifungal drug susceptibility. mBio 10(1), e01726-18 (2019).
MedlineGoogle Scholar

Vol. 18, No. 2

Supplemental Materials

Metrics

Downloaded 122 times

History

Received 7 June 2022

Accepted 2 December 2022

Published online 20 January 2023

Published in print January 2023

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fmb-2022-0133

Author contributions

Each author has contributed significantly to this work. LC Silva, S Cunha and M Pereira contributed to designing the manuscript and data analysis. RF dos Santos Filho and S Cunha synthesized the compounds, F Terra Martins performed X-ray analysis and LC Silva performed the biological assays. AA de Oliveira performed the computational assays. S Cunha, M Pereira and CM de Almeida Soares contributed to fundraising for the research. All authors contributed to the writing and preparation of the manuscript and approval of the final version of the manuscript.

Acknowledgments

The authors thank Openeye for providing the academic license for the programs used for Molecular Docking.

Financial & competing interests disclosure

This work was performed at Universidade Federal de Goiás and was supported by Ministério da Ciência e Tecnologia/Conselho Nacional de Desenvolvimento Científico e Tecnológico (MCTI/CNPq); Fundo Nacional de Desenvolvimento Científico e Tecnológico (FNDCT); Fundação de Amparo à Pesquisa do Estado de Goiás (FAPEG); Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB); Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Finance Code 001; CAPES); Financiadora de Estudos e Projetos (FINEP); Programa de Apoio a Núcleos de Excelência (PRONEX); and Instituto Nacional de Ciência e Tecnologia de Estratégias de Interação Patógeno-Hospedeiro (INCT-IPH). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download

3-phenacylideneoxindoles as a new class of antifungal compounds against Paracoccidioides spp.

Abstract

Plain language summary

References